OCSIAL ASIA PACIFIC (hereinafter referred to as OCSIAL) announced on the 26th that it has signed a long-term partnership with DUKSAN Pharmaceuticals (hereinafter referred to as DUKSAN) for the development and production of single-wall carbon nanotube (SWCNT)-based products.

Under the partnership, Deoksan has obtained an exclusive license to produce, sell and supply OCIAL’s ‘TUBALL’-based products in Korea and is currently constructing a 4,000 square meter customized manufacturing center at its manufacturing facility in Jincheon.



While strictly managing the production process of the customized manufacturing center, OCIAL provides initial training to Deoksan experts and supports necessary technology and marketing.

The custom manufacturing center supplies suspensions used in a variety of fields, from industrial sites to research institutes. Deoksan Pharmaceutical Industry produces ▲TUBAL BATT, which is used in lithium-ion batteries and energy applications in the domestic market; ▲TUBALL INK, which increases the electrical conductivity of transparent conductive films; ▲TUBALL COAT, which is added to the development of paints and coatings; and ▲TUBALL RUBBER, which improves the conductivity and properties of latex and synthetic rubber.

Victor Kim, CEO of Oxial Asia Pacific, said, “This partnership with Deoksan Pharmaceuticals is significant in that it enables the manufacture of suspensions used in various fields, not just the simple supply of SWCNTs. In the future, we will expand the areas in which Tuval can be used to include polymer composites, rubber, transparent conductive films (TCF), paints, and coatings.”

Koh Young-chae, CEO of Deoksan Pharmaceutical Industry, said, “Through our collaboration with Oxyal, we have been able to produce and supply more competitive tubular-based products. Through our long-term partnership in the future, we will strengthen our competitiveness as a chemical reagent company and lead the industry.”